Bile Acid Exposure Up-regulates Tuberous Sclerosis Complex 1/Mammalian Target of Rapamycin Pathway in Barrett's-Associated Esophageal Adenocarcinoma

CMUR > College of Medicine > Graduate Institute of Cancer Biology > Journal articles > Item 310903500/7082

Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/7082

Title:	Bile Acid Exposure Up-regulates Tuberous Sclerosis Complex 1/Mammalian Target of Rapamycin Pathway in Barrett's-Associated Esophageal Adenocarcinoma
Authors:	(Chia-Jui Yen);(Julie G. Izzo);(Dung-Fang Lee);(Sushovan Guha);(Yongkun Wei);(Tsung-Te Wu);(Chun-Te Chen);(Hsu-Ping Kuo);(Jung-Mao Hsu);(Hui-Lung Sun);(Chao-Kai Chou);(Navtej S. Buttar);(Kenneth K. Wang);(Peng Huang);(Jaffer Ajani);洪明奇(Mien-Chie Hung)*
Contributors:	醫學院癌症生物學研究所;中國附醫院長室
Keywords:	bile acid;IKKβ/TSC1/mTOR;Barrett's associated esophageal adenocarcinoma
Date:	2008-04
Issue Date:	2009-08-26 16:11:22 (UTC+8)
Abstract:	University of Texas M. D. Anderson Multidisciplinary Esophageal Research Grant; RiverKreek Foundation, Dallas, Cantu, Smith, and Park Families; a predoctoral fellowship from the U.S. Army Breast Cancer Research Program, grant W81XWH-05-1-0252 & W81XWH-06-1-0709; T.C. Hsu Endowed Memorial Scholarship;Andrew Sowell-wade Huggins Scholarship; Presidents' Research Scholarship from University of Texas Graduate School of Biomedical Sciences at Houston; Taiwan Merit Scholarship from National Science Council of Taiwan Barrett's esophagus, a columnar metaplasia of the lower esophagus epithelium related to gastroesophageal reflux disease, is the strongest known risk factor for the development of esophageal adenocarcinoma (EAC). Understanding the signal transduction events involved in esophageal epithelium carcinogenesis may provide insights into the origins of EAC and may suggest new therapies. To elucidate the molecular pathways of bile acid–induced tumorigenesis, the newly identified inflammation-associated signaling pathway involving IB kinases β (IKKβ), tuberous sclerosis complex 1 (TSC1), and mammalian target of rapamycin (mTOR) downstream effector S6 kinase (S6K1) was confirmed to be activated in immortalized Barrett's CPC-A and CPC-C cells and esophageal cancer SEG-1 and BE3 cells. Phosphorylation of TSC1 and S6K1 was induced in response to bile acid stimulation. Treatment of these cells with the mTOR inhibitor rapamycin or the IKKβ inhibitor Bay 11-7082 suppressed bile acid–induced cell proliferation and anchorage-independent growth. We next used an orthotopic rat model to evaluate the role of bile acid in the progression of Barrett's esophagus to EAC. Of interest, we found high expression of phosphorylated IKKβ (pIKKβ) and phosphorylated S6K1 (pS6K1) in tumor tissues and the Barrett's epithelium compared with normal epithelium. Furthermore, immunostaining of clinical EAC tissue specimens revealed that pIKKβ expression was strongly correlated with pS6K1 level. Together, these results show that bile acid can deregulate TSC1/mTOR through IKKβ signaling, which may play a critical role in EAC progression. In addition, Bay 11-7082 and rapamycin may potentially be chemopreventive drugs against Barrett's esophagus–associated EAC.
Relation:	CANCER RESEARCH 68(8 )2632 ~2640
Appears in Collections:	[Graduate Institute of Cancer Biology] Journal articles

Files in This Item:

File	Size	Format
	58Kb	Unknown	371	View/Open

Loading...